Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial

Phase 2 ◽

Single Centre ◽

Phase 2 Trial ◽

Resin Microspheres

6517 POSTER Sunitinib and Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma (HCC)- Final Results of a Phase 2 Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)71828-7 ◽

2011 ◽

Vol 47 ◽

pp. S447

Author(s):

R. Iyer ◽

G. Fetterly ◽

A. Groman ◽

A. Hutson ◽

N. Khushalani ◽

...

Keyword(s):

Transarterial Chemoembolization ◽

Phase 2 ◽

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30011-5 ◽

2020 ◽

Vol 21 (4) ◽

pp. 571-580 ◽

Cited By ~ 33

Author(s):

Shukui Qin ◽

Zhenggang Ren ◽

Zhiqiang Meng ◽

Zhendong Chen ◽

Xiaoli Chai ◽

...

Keyword(s):

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Parallel Group ◽

Previously Treated

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Journal of Hematology & Oncology ◽

10.1186/s13045-020-00886-2 ◽

2020 ◽

Vol 13 (1) ◽

Cited By ~ 2

Author(s):

Feng Wang ◽

Shukui Qin ◽

Xinchen Sun ◽

Zhenggang Ren ◽

Zhiqiang Meng ◽

...

Keyword(s):

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Endothelial Proliferation

Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma

Cancer ◽

10.1002/cncr.25889 ◽

2011 ◽

Vol 117 (14) ◽

pp. 3187-3192 ◽

Cited By ~ 58

Author(s):

Weijing Sun ◽

Davendra Sohal ◽

Daniel G. Haller ◽

Kristine Mykulowycz ◽

Mark Rosen ◽

...

Keyword(s):

Phase 2 ◽

P-135 Pembrolizumab/quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress

Annals of Oncology ◽

10.1016/j.annonc.2021.05.190 ◽

2021 ◽

Vol 32 ◽

pp. S144-S145

Author(s):

D. Li ◽

A. Cheng ◽

H. Lim ◽

J. Llovet ◽

Y. Zhu ◽

...

Keyword(s):

Phase 2 ◽

Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(20)30290-9 ◽

2021 ◽

Vol 6 (1) ◽

pp. 17-29 ◽

Cited By ~ 1

Author(s):

Etienne Garin ◽

Lambros Tselikas ◽

Boris Guiu ◽

Julia Chalaye ◽

Julien Edeline ◽

...

Keyword(s):

Radiation Therapy ◽

Locally Advanced ◽

Selective Internal Radiation Therapy ◽

Phase 2 ◽

Internal Radiation ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

OP0002 A randomised, single-centre phase 2 study of ginsenoside Rg3 plus transarterial chemoembolisation (TACE) versus TACE alone in Chinese patients with advanced hepatocellular carcinoma

European Journal of Cancer ◽

10.1016/j.ejca.2015.06.007 ◽

2015 ◽

Vol 51 ◽

pp. e1

Author(s):

Bo Zhou ◽

Zhiping Yan ◽

Rong Liu ◽

Sheng Qian ◽

Xudong Qu ◽

...

Keyword(s):

Chinese Patients ◽

Phase 2 ◽

Ginsenoside Rg3 ◽

Single Centre ◽

Transarterial Chemoembolisation ◽

Phase 2 Study

6517 International phase 2 trial of ABT-869 in patients with advanced hepatocellular carcinoma (HCC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71239-x ◽

2009 ◽

Vol 7 (2) ◽

pp. 366-367 ◽

Cited By ~ 4

Author(s):

H.C. Toh ◽

P. Chen ◽

J.J. Knox ◽

S. Gill ◽

D.M. Carlson ◽

...

Keyword(s):

Phase 2 ◽

Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a non-randomized, open-label, phase 2 trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-2571 ◽

2020 ◽

pp. clincanres.2571.2020

Author(s):

Jianming Xu ◽

Jie Shen ◽

Shanzhi Gu ◽

Yun Zhang ◽

Lihua Wu ◽

...

Keyword(s):

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Faculty Opinions recommendation of Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.733372389.793574891 ◽

2020 ◽

Author(s):

Man-Fung Yuen ◽

Lung-Yi Mak

Keyword(s):

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Previously Treated